United States
(EN)
|
Americas
Europe/Middle East/Africa
VITROS® XT MicroSlides pair tests that physicians typically order together while maintaining the high-quality results that physicians expect from Ortho’s MicroSlide technology.
The D-Dimer assay detects the presence of intravascular coagulation and fibrinolysis through the measurement of the fibrin degradation product D-Dimer.
Read the article from the Rochester Business Journal.
Learn what happened after a fire at a manufacturing plant disrupted a local water supply and got a lab thinking about its reliance on water.
Read the article in FierceBiotech.
Read the MLO interview with Ortho’s head of business fields – transfusion medicine.
Ortho has announced the launch of four new key assays in collaboration with Beijing Leadman Biochemistry Co., Ltd., based in Beijing, to meet the demand of the rapidly growing diagnostics market in China.
Ortho’s VITROS® XT MicroSlide is powered by DIGITAL CHEMISTRY™, an optics technology that gleans significantly more information from each test than before, improving performance, saving time and space in the lab, increasing productivity, with less patient sample required for testing.
Ortho has been awarded a Stevie® Award for Customer Service Department of the Year for its Ortho Care™ support program.
Dubbed the Ortho neXT Tour, the 18-wheeled mobile experience center is designed to demonstrate Ortho's newest offerings for the clinical lab.
Ortho has appointed Robert Yates as chairman and chief executive officer effective February 12, 2019. Robert Yates will succeed Dr. Martin Madaus, who is retiring after serving as chairman and CEO of Ortho since June 2014.
Ortho's VITROS® Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS® HIV Combo test) has received approval from the U.S. Food and Drug Administration for use on Ortho’s VITROS® ECi/ECiQ Immunodiagnostic Systems. It was previously approved for use on Ortho’s VITROS® 5600 Integrated System and Ortho’s VITROS® 3600 Immunodiagnostic System.
The VITROS® Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS® HIV Combo test) has received approval from the U.S. Food and Drug Administration for use on Ortho’s VITROS® 5600 Integrated System.
Ortho Clinical Diagnostics has announced that it has received FDA clearance for Ortho’s VITROS® XT 7600 Integrated System.
Becker’s Hospital Review featured an article by Ortho’s Jay Snyder on how to measure the immense value clinical labs drive throughout the health care system.
Ortho will highlight how connectivity can improve operational excellence in transfusion medicine labs at the 2018 AABB Annual Meeting in Boston, Oct. 13-16, and it will underscore the point during a special customer event at the New England Aquarium.
Ortho is continuing to expand its menu by offering three new assays to customers.
Ortho has been named one of India’s Great Mid-Size Workplaces 2018 by Great Place to Work® Institute, an institute focused on building, sustaining and recognizing High Trust- High Performing Cultures™.
Ortho Clinical Diagnostics (Ortho) has announced the introduction of its next-generation Anti-T. cruzi assay, with CE Mark approval and approval for use in Mexico.
Ortho has been named The Trailblazer 2018 Company of the Year in the Medical Device/Diagnostics Category by PM360, a respected publication for marketing decision-makers in the pharmaceutical, biotech and medical device industries.
The Ortho Care™ service and support unit once again received the Services Excellence Award in the Health & Wellness Category from ASSOCHAM, a not-for-profit apex trade association in India.
Jay Snyder, head of Business Fields – Clinical Lab Platforms, discusses with MD+DI Ortho’s VITROS® XT 7600 and its impact on the clinical lab environment.
Ortho’s Jay Snyder spoke to SelectScience at AACC 2018. Watch the video for a discussion on Ortho’s recently CE Marked VITROS® XT 7600 Integrated System.
Jay Snyder, head of Business Fields – Clinical Lab Platforms, discusses Ortho’s new VITROS® XT systems with 360Dx.
Ortho Clinical Diagnostics, for the third year in a row, had its Ortho Care™ service and support program ranked as the highest-ranked original equipment manufacturer for overall service performance in the diagnostics industry.
Ortho will officially unveil the VITROS® XT 7600 Integrated System*, now available in numerous countries that accept CE Mark, at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. It also will present seven scientific posters highlighting performance of assays that are part of its offerings for sepsis, Chagas, diabetes and other conditions.
Kalorama Information, via Le Lezard, cites Ortho’s poster presentation on the effectiveness of our forthcoming T. cruzi assay among "Big Developments at AACC 2018."
Nadav Kaufman, senior director of product management for clinical lab menu at Ortho Clinical Diagnostics, shared with CAP Today his view on customer priorities when choosing analyzers for their labs.
Ortho Clinical Diagnostics has received CE Mark for Ortho’s VITROS® XT 7600 Integrated System. By combining Ortho’s proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously, Ortho is introducing digital chemistry to clinical lab management.
Ortho Clinical Diagnostics (Ortho), in collaboration with Diazyme Laboratories, Inc. is offering three new Microtip Partnership Assays.
Ortho Chairman and CEO Martin Madaus tells Ortho’s successful carve-out, growth story to PM360.
Ortho Clinical Diagnostics (Ortho), has been named Legal Department of the Year by New Jersey Law Journal for in-house professional excellence.
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that its in-house Legal and Compliance Department has been named the Transatlantic Legal Department of the Year.
The New Jersey Law Journal features a Q&A with Michael Schlesinger, our general counsel. In the article, Michael discusses how the global Legal and Compliance department worked through our corporate carve-out, while also providing legal support to Ortho.
Ortho will host a satellite symposium, co-sponsored with Quotient Limited (QTNT), titled “Responding to the Challenges of Resource Constraints in Transfusion Diagnostics.” during the 35th International Congress of the International Society of Blood Transfusion (ISBT).
“It is about time healthcare administrators acknowledge this tremendous value and stop looking at the laboratory as a cost center,” argues Dr. Fernando Chaves, Ortho’s top scientist, in his recent article in MedCity News.
Ortho has announced an international distribution and co-promotion agreement with Sentinel Diagnostics, to provide a wide-range C-Reactive Protein assay, the CRP Ultra (MP) Assay.
Ortho Clinical Diagnostics India has been certified as a Great Place to Work by the Great Place to Work® Institute, India.
Ortho is hosting the Ortho Lab Leader Scientific Summit on May 8 and 9 at the Conrad Hotel in Seoul, South Korea.
Our chairman and CEO. Martin Madaus. spoke to The South China Morning Post about our global growth and momentum in diagnostics and our strategy in China.
Ortho welcomes and supports the inclusion of the biomarkers in the NephroCheck® Test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute kidney injury (AKI), in consensus guidelines released by ERAS® Cardiac Surgery.
Ortho Clinical Diagnostics has been selected for a gold-level Edison Award™ in the Best New Product Awards™ category for its VITROS® NEPHROCHECK® Test. VITROS NEPHROCHECK is the first fully automated risk assessment tool for predicting acute kidney injury (AKI), a serious and potentially fatal condition affecting hospital patients worldwide.
Ortho Clinical Diagnostics has announced an international distribution and co-promotion agreement with Thermo Fisher Scientific to provide 14 assays used to monitor therapeutic drugs, immunosuppressive drugs and drugs of abuse. The agreement is part of Ortho’s ongoing MicroTip Partnership Assays program.
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it has been recognized with a global LeFonti AWARD® for Excellence in Innovation in the diagnostics sector.
The ORTHO CONNECT V2.0 middleware solution received 510(k) clearance by the U.S. Food and Drug Administration.
Ortho will host its second annual Transfusion Medicine Summit in Xi’an, China, on March 17, 2018.
Ortho Clinical Diagnostics has announced the launch of Ortho’s VITROS® Immunodiagnostic Products C-peptide Reagent Pack and Calibrators, which broadens the company’s menu of tests for all aspects of diabetes and other pancreatic disorders. The assay is now commercially available in the U.S. and countries that accept the CE Mark.
Our chairman and CEO, Martin Madaus, spoke to the publication Medical Marketing & Media.
Ortho’s Jay Snyder weighs in on the trend of automation moving down the test volume continuum in this insightful piece for Medical Laboratory Observer.
Welsh First Minister Carwyn Jones today visited our Pencoed, Wales, office, where we are increasing our production to meet rising global demand for our in vitro diagnostics technology.
U.S.-headquartered Ortho is the only diagnostics company to be recognized by Asia's largest daily business publication
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced the launch of VITROS® ALTV Slides, a new and novel method for the measurement of alanine aminotransferase (ALT), a key liver function enzyme found in serum and plasma, utilizing dry slide technology.
FDA Approves VITROS® Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator
Ortho Clinical Diagnostics and Sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure
A new article in the health care industry journal The Pathologist describes how the biomarkers in Ortho’s VITROS® NEPRHOCHECKTM assay work to detect risk of acute kidney injury.
Ortho’s VITROS® NEPHROCHECK™ Wins International Award for 'Outstanding Innovation'
Dr. Martin Madaus speaks to Huffington Post about why he recommends running “The Beast,” how to build social capital and how to manage a successful corporate carveout while maintaining steady growth.
Ray Jakubowicz, Innovation Fellow at Ortho, shared his perspective on the future of optics, photonics and imaging research, in a recent video by NY State’s Empire State Development project.
Immunohematology System from Ortho Clinical Diagnostics Now Commercially Available in China
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body Now Available on Ortho’s VITROS® 4600 and VITROS® 5600
Industry Workshop to Address Clinical Outcomes of Titration Studies Using ID-MTS™ Gel Test Method
“Ortho Sera helps increase confidence in the lab and allow staff to focus on improving lab efficiency,” says Robert Yates, chief operating officer at Ortho Clinical Diagnostics. “This addition our comprehensive, integrated product portfolio furthers our goal of helping lab technologists deliver reliable results to their patients, despite pressures caused by limited resources and staff constraints.”
RANDOMIZED CONTROL TRIAL REPORTS 66% REDUCTION IN MODERATE TO SEVERE AKI; 5-DAY REDUCTION IN TOTAL HOSPITAL STAY
Learn more about automation and the recent flowering of innovation in blood banking.
Recognition is the latest in a string of No. 1 ratings and rankings for holistic Ortho Care™ Support Program.
Approval exemplifies Ortho’s commitment to expand menu while streamlining lab operations
ORTHO™ Sera is the only comprehensive menu of antisera for extended antigen phenotyping available in a gel testing format in the U.S.
How to Manage a Large, Complex Corporate Carve-Out Well: Ortho CEO Dr. Martin Madaus on CNBC's Squawk Box
Assay plays key role in aiding clinicians in the assessment and treatment of sepsis and septic shock
In Vitro Diagnostics Industry Rankings Published by ServiceTrak™
Activities at the annual meeting of American Association for Clinical Chemistry will demonstrate Ortho’s focus on immunodiagnostics and acute kidney injury
Assay will be commercially available in third quarter in countries accepting CE Mark
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that Ortho’s VITROS®
Sponsored educational sessions and product demonstrations at IFCC’s EUROMEDLAB Athens conference for lab professionals
AKI, the sudden loss of kidney function, can develop without warning and potentially lead to kidney failure and death. Known as a silent killer, AKI is as common and twice as deadly as a heart attack.
Learn more
t’s not a sprint, it’s a decathlon. Ortho Chairman and CEO Martin Madaus on innovation within the in vitro diagnostics industry.
Ortho Clinical Diagnostics has been awarded an Edison Award™ for Global Product Innovation, for its ORTHO VISION® Platform.
Ortho was featured in a recent edition of the Rochester Business Journal regarding our commitment to global R&D and our customers.
Ortho will sponsor five author presentations and four poster presentations at MEDLAB Asia Pacific Exhibition & Congress 2017
Agreement gives Ortho expanded distribution rights in Europe for the NephroCheck Test on the ASTUTE140 platform.
Ortho Care™ Support Program Recognized As Best-in-Class Service and Support for Hospitals, Hospital Networks, Blood Banks & Labs
Latest submissions exemplify Ortho’s commitment to expand menu while streamlining lab operations
ORTHO VISION® Analyzer Wins International Awards for ‘Outstanding Innovation’ and ‘Outstanding Product/Service’
This accomplishment is recognition of the ORTHO VISION® platform’s value to customers, and represents faster growth than Ortho’s previous products in this space.
ORTHO CONNECT is a comprehensive, integrated, customizable intermediary software that streamlines laboratory operations, allowing lab professionals to manage multiple instruments from a single console
ORTHO CONNECT™ V2.0 is now commercially available in Europe and other countries accepting CE Mark
Michael S. Iskra details steps laboratories can take to be an integral force in driving hospitals’ strategic priorities.
Alex Socarrás discusses our strategy, new products, our customer focus and trends in the clinical laboratory space in Latin America and worldwide.
Ortho’s growth and momentum were covered in the first edition of the new diagnostics-focused publication, 360Dx.
Read the recent CAP Today article on the FDA Clearance of the ORTHO VISION® Max Analyzer for High-Volume Transfusion Medicine Labs.
Ortho's momentum is growing, as we launched two new products to enable better, faster diagnostics in October, 2016. Read about our VITROS® Automation Solutions in FDA News.
Open, flexible and scalable platform empowers laboratory clinicians to take total facility control
Two Ortho colleagues recently guest-blogged for AABB about workshops on mass transfusion protocol in the wake of tragic events, and reducing the risk of alloimmunization during blood transfusion.
New Immunohematology System from Ortho Clinical Diagnostics Expands ORTHO VISION® Platform; Now Commercially Available in the United States
Customer event will feature analysis of mass transfusion protocol implementation in the wake of Orlando attack
Heidi Casaletto, Ortho’s VP of Transfusion Medicine, was featured in the recent article, "Building a Safer Blood Supply,” in CLP Magazine
A Recent Video on Customer Experience of Ortho Clinical Diagnostics’ Lab Data Management Solution at Marion General Hospital
"This type of support is now more critical than ever," said Ortho’s Alex Socarrás in a recent article in CLP Magazine.
Ortho Clinical Diagnostics was featured in a recent article in Clinical Lab Products magazine
Best-in-Class Service and Support Program for Hospitals, Hospital Networks, Blood Banks and Labs
Ortho will present seven scientific posters on its assays and display six products at its booth at the 2016 AACC annual meeting.
Ortho will present seven scientific posters on its assays and display six products at its booth at the 2016 AACC annual meeting.
Ortho Clinical Diagnostics announced that it was ranked higher than any other company for overall service performance by an OEM in the in vitro diagnostics industry.
Karen Davis-Fleischer, VP Business Fields at Ortho, was featured in a recent article in Clinical Lab Products
Ortho Clinical Diagnostics today announced that its ORTHO VISION® Analyzer has been recognized with a 2016 Innovation Award by members of Premier, Inc.
New Test Expands Infectious Disease Assay Portfolio; Will Become Commercially Available in Europe and Other Countries that Accept CE Mark This Month
Beckman Coulter Diagnostics to Place Ortho’s VITROS® 3600 Systems in Very High-Volume Labs
Beckman Coulter Diagnostics to Place Ortho’s VITROS® 3600 Systems in Very High-Volume Labs
Ortho Clinical Diagnostics has presented the initial performance capabilities of its fourth-generation HIV Test in development.
Ortho Clinical Diagnostics today announced that ORTHO™ Sera, a fully automated solution for extended antigen phenotyping, is now available on the ORTHO VISION® Analyzer.
Ortho’s Chairman and CEO speaks about the Company’s progress as an independent company in this Q&A interview with FierceMedicalDevices
Jennifer Paine, Ortho’s EVP of Worldwide Quality, Regulatory and Compliance, has been named to Becker’s Hospital Review’s prestigious “Women to Watch in Med Tech” list.
Ortho Clinical Diagnostics presented a scientific poster at the 2016 HIV Diagnostics Conference on the performance of its Fourth-Generation HIV Test in development.
Our new infographic explores how generalists and specialists differ and the unique ways in which they collaborate in the blood banking field.
Digital Rochester has announced the 14 nominees for its 2016 Technology Woman of the Year award, including Mary Pat Cottengim, human factors & usability lead for Ortho Clinical Diagnostics.
Waterloo's Covenant Medical Center is the first medical facility in Iowa to install the ORTHO VISION™ Analyzer.
Ortho's Chairman and CEO speaks about the Company's pioneering spirit and how it is driving forward as a global partner for clinical laboratories and transfusion medicine.
Ortho Clinical Diagnostics today announced that Terre Haute Regional Hospital is the first U.S. medical center to install the ORTHO VISION™ Analyzer.
Newton Medical Center is the first hospital in the U.S. to order new transfusion medicine analyzer.
Jennifer Paine, executive vice president of worldwide quality, Regulatory & Compliance, has been recognized by the Regulatory Affairs Professionals Society as a 2015 Top 10 Honoree.
Ortho Clinical Diagnostics' ORTHO VISION™ Max, a fully automated blood analyzer for high-volume transfusion medicine laboratories, receives CE Mark clearance.
Ortho Clinical Diagnostics receives 510(k) clearance for ORTHO VISIONTM Analyzer, making it commercially available in the United States.
Ortho Clinical Diagnostics presents data on five assays in development at the American Association for Clinical Chemistry's annual meeting.
Ortho Clinical Diagnostics receives FDA 510(k) clearance for VITROS® Chemistry Products HbA1c Reagent Kit, an enhanced diabetes testing assay.
Ortho Clinical Diagnostics and Quotient announce an agreement to commercialize innovative transfusion medicine diagnostic platform MosaiQTM
Ortho Clinical Diagnostics sponsors the American Association for Clinical Chemistry webinar: Clinical Application of Recently Approved Biomarkers of Acute Kidney Injury.
Ortho Clinical Diagnostics receives CE Mark for ORTHO VISION™ Analyzer to take full automation transfusion medicine testing to the next level.
Ortho Clinical Diagnostics receives CE Mark for VITROS® Chemistry Products HbA1c Reagent Kit, an enhanced diabetes testing assay.
Ortho Clinical Diagnostics signs agreement with Astute Medical, Inc. to commercialize and develop innovative acute kidney injury tests.
Ortho Clinical Diagnostics announces executive leadership appointments as it becomes an independent, stand alone company.
Find out more about who we are, meet our leadership team, and explore our history
Learn more
Back to Top